TY - JOUR
T1 - Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy
T2 - Data from the DA-COVID-19 registry
AU - DA‐COVID‐19 study group
AU - Chiricozzi, Andrea
AU - Talamonti, Marina
AU - De Simone, Clara
AU - Galluzzo, Marco
AU - Gori, Niccolò
AU - Fabbrocini, Gabriella
AU - Marzano, Angelo Valerio
AU - Girolomoni, Giampiero
AU - Offidani, Annamaria
AU - Rossi, Maria Teresa
AU - Bianchi, Luca
AU - Cristaudo, Antonio
AU - Fierro, Maria Teresa
AU - Stingeni, Luca
AU - Pellacani, Giovanni
AU - Argenziano, Giuseppe
AU - Patrizi, Annalisa
AU - Pigatto, Paolo
AU - Romanelli, Marco
AU - Savoia, Paola
AU - Rubegni, Pietro
AU - Foti, Caterina
AU - Milanesi, Nicola
AU - Belloni Fortina, Anna
AU - Bongiorno, Maria Rita
AU - Grieco, Teresa
AU - Di Nuzzo, Sergio
AU - Fargnoli, Maria Concetta
AU - Carugno, Andrea
AU - Motolese, Alberico
AU - Rongioletti, Franco
AU - Amerio, Paolo
AU - Balestri, Riccardo
AU - Potenza, Concetta
AU - Micali, Giuseppe
AU - Patruno, Cataldo
AU - Zalaudek, Iris
AU - Lombardo, Maurizio
AU - Feliciani, Claudio
AU - Di Nardo, Lucia
AU - Guarneri, Fabrizio
AU - Peris, Ketty
N1 - Publisher Copyright:
© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - BACKGROUND: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. METHODS: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. RESULTS: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. CONCLUSIONS: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
AB - BACKGROUND: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. METHODS: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. RESULTS: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. CONCLUSIONS: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
KW - atopic dermatitis
KW - COVID
KW - SARS‐CoV
UR - http://www.scopus.com/inward/record.url?scp=85106431059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106431059&partnerID=8YFLogxK
U2 - 10.1111/all.14767
DO - 10.1111/all.14767
M3 - Article
C2 - 34152613
AN - SCOPUS:85106431059
VL - 76
SP - 1813
EP - 1824
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0105-4538
IS - 6
ER -